Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS phase 3 study of apalutamide in high-risk localized or locally advanced prostate cancer receiving primary radiation therapy
2023-505246-26-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Apalutamide arm with Placebo arm (2 arms). Primary endpoint: Metastasis-free survival. Planned start Jan 2016; status: authorised.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-505246-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505246-26-00.